Clinical Trial Result Information
Title of Study:
An open, prospective, randomized, controlled study comparing CellCept® (mycophenolate mofetil, MMF) administered as a component of tacrolimus based immunosuppression therapy, at a loading dose of 3 g daily during the initial post-transplant period versus CellCept® administered at a dose of 2 g daily, in recipients of renal allografts: a multicentre pilot study
Fast Facts:
| Protocol number: | ML18496 |
| Sponsor: | Hoffmann-La Roche Ltd |
| Company division: | Pharmaceutical |
| Product name: | CellCept |
| Generic name: | mycophenolate mofetil |
| Phase of development: | III |
| Therapeutic area, approved indication: | Kidney Transplantation |
| Date of report: | To be Published |
Clinical study summary:
This trial does not yet have clinical trial results posted on this website. All trial results will be posted within one year of approval or one year after trial completion, unless the release of information is restricted due to journal publication timing or pending regulatory filing. For further information on the timing of posting clinical trial results please consult the Roche policy for posting information on this website.
Click here for the protocol registry listing of this trial.
